These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 21092710

  • 1. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.
    Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, Cicero AF.
    J Pharm Pharm Sci; 2010; 13(3):378-90. PubMed ID: 21092710
    [Abstract] [Full Text] [Related]

  • 2. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients.
    Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, Cicero AF.
    J Clin Pharm Ther; 2011 Oct; 36(5):592-601. PubMed ID: 21070297
    [Abstract] [Full Text] [Related]

  • 3. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Palumbo I, Randazzo S, Cicero AF.
    Intern Med; 2010 Oct; 49(16):1717-25. PubMed ID: 20720348
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
    Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
    Fundam Clin Pharmacol; 2011 Oct; 25(5):642-51. PubMed ID: 21077943
    [Abstract] [Full Text] [Related]

  • 6. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients.
    Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
    Endocr J; 2010 Oct; 57(9):777-86. PubMed ID: 20683173
    [Abstract] [Full Text] [Related]

  • 7. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
    Derosa G, Cicero AF, D'Angelo A, Fogari E, Maffioli P.
    J Clin Pharm Ther; 2012 Apr; 37(2):187-95. PubMed ID: 21812797
    [Abstract] [Full Text] [Related]

  • 8. Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Palumbo I, Randazzo S, Cicero AF.
    Metabolism; 2011 Mar; 60(3):421-9. PubMed ID: 20423740
    [Abstract] [Full Text] [Related]

  • 9. Exenatide versus glibenclamide in patients with diabetes.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.
    Diabetes Technol Ther; 2010 Mar; 12(3):233-40. PubMed ID: 20151774
    [Abstract] [Full Text] [Related]

  • 10. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 11. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
    Derosa G, Mereu R, Salvadeo SA, D'Angelo A, Ciccarelli L, Piccinni MN, Ferrari I, Gravina A, Maffioli P, Cicero AF.
    Intern Med; 2009 Apr; 48(5):265-71. PubMed ID: 19252346
    [Abstract] [Full Text] [Related]

  • 12. Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects.
    Tankova T, Dakovska G, Lazarova M, Dakovska L, Kirilov G, Koev D.
    Acta Diabetol; 2004 Dec; 41(4):146-53. PubMed ID: 15660196
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [Abstract] [Full Text] [Related]

  • 15. [Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial].
    Tong NW, Ran XW, Li QF, Tang BD, Li R, Yang FY, Liu YP, Li XJ.
    Zhonghua Nei Ke Za Zhi; 2005 Sep; 44(9):659-63. PubMed ID: 16202254
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes.
    Hung YJ, Chen YC, Pei D, Kuo SW, Hsieh CH, Wu LY, He CT, Lee CH, Fan SC, Sheu WH.
    Diabet Med; 2005 Aug; 22(8):1024-30. PubMed ID: 16026368
    [Abstract] [Full Text] [Related]

  • 18. A review of the metabolic effects of sibutramine.
    Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS.
    Curr Med Res Opin; 2005 Mar; 21(3):457-68. PubMed ID: 15811215
    [Abstract] [Full Text] [Related]

  • 19. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation.
    Derosa G, Ragonesi PD, Fogari E, Cicero AF, Bianchi L, Bonaventura A, Romano D, Maffioli P.
    Fundam Clin Pharmacol; 2014 Apr; 28(2):221-9. PubMed ID: 23039403
    [Abstract] [Full Text] [Related]

  • 20. The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects.
    Sabuncu T, Ucar E, Birden F, Yasar O.
    Diabetes Nutr Metab; 2004 Apr; 17(2):103-7. PubMed ID: 15244102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.